Table 1 Demographics for the Thalassemia Longitudinal Cohort (TLC) participants completing the Beliefs in Medicines Questionnaire (BMQ) (N=371) a
Age (years), mean (SD), range | 24.0 (12.6), 5.0 - 58.3 |
Gender, N (%) | |
Male | 176 (47.4%) |
Female | 195 (52.6%) |
Race, N (%) | |
White | 181 (49.6%) |
Asian | 163 (44.7%) |
Other | 21 (5.8%) |
Country, N (%) | |
US | 269 (72.5%) |
Canada | 64 (17.3%) |
UK | 38 (10.2%) |
Thalassemia diagnosis, N (%) | |
β-thal transfused 8+ times | 279 (75.2%) |
β-thal transfused <8 times | 28 (7.6%) |
β-thal not transfused | 4 (1.1%) |
E-β-thal transfused 8+ times | 32 (8.6%) |
E-β-thal transfused <8 | 8 (2.2%) |
E-β-thal not transfused | 1 (0.3%) |
HbH | 6 (1.6%) |
HbH Constant Spring | 8 (2.2%) |
Alpha-thalassemia | 5 (1.4%) |
Chelation, N (%) | |
None | 30 (8.1%) |
Deferoxamine (DFO) | 89 (24.0%) |
Deferasirox | 200 (53.9%) |
Deferiprone | 15 (4.0%) |
Deferoxamine + Deferasirox | 11 (3.0%) |
Deferoxamine + Deferiprone | 26 (7.0%) |
Serum ferritin (ng/ml), median (range) b | 1296.8 (75.0 - 18453.5) |
Liver iron concentration (LIC in mg Fe/g dry), median (range) b | 8.2 (0.4 – 67.9) |